This announcement is a separate document:
北京国枫律师事务所关于北京康辰药业股份有限公司2023年限制性股票激励计划预留授予、首次授予部分第一个解除限售期解除限售条件成就及回购注销事项的法律意见书
Legal Opinion of Beijing Guofeng Law Firm on Beijing Kangchen Pharmaceutical Co., Ltd.\'s 2023 Restricted Stock Incentive Plan Reserve Grant and First Grant of Part 1 of the First Release Period to Lift Sales Restriction Conditions and Repurchase Cancellation Matters
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.